Article

Alcon closes acquisition of LenSx

Alcon Inc. has received regulatory approval of and has closed the acquisition of LenSx Lasers Inc.

Huenenberg, Switzerland-Alcon Inc. has received regulatory approval of and has closed the acquisition of LenSx Lasers Inc.

LenSx has developed a customizable, image-guided femtosecond laser to perform certain cataract surgery steps. It is designed to create an anterior capsulorhexis of exact diameter and fragment the lens for more efficient removal. It is the first such laser to receive FDA clearance for use as a part of cataract surgery, according to the company. Alcon anticipates that the proprietary femtosecond laser will be commercially available in the United States beginning in the fourth quarter of this year and in other countries in 2011.

“We are extremely pleased with the addition of the LenSx technology to Alcon’s current microincisional cataract surgery product portfolio,” said Stuart Raetzman, vice president, global marketing and area president for the United States.

LenSx President and Chief Executive Officer Ronald Kurtz, MD, said, “The LenSx team is thrilled to be a part of Alcon.”

Alcon paid a base purchase price of $361.5 million in cash to LenSx shareholders for their shares, plus committed to pay maximum contingent payments of $382.5 million based on the achievement and over-achievement of future femtosecond unit and procedure fee revenue milestones.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.